Improved Drug-Response Prediction Model of APC Mutant Colon Cancer Patient-Derived Organoids for Precision Medicine
Colorectal cancer is the third most common cancer in the world, with an annual incidence of 2 million cases. The success of first-line chemotherapy plays a crucial role in determining the disease outcome. Therefore, there is an increasing demand for precision medicine to predict drug responses and o...
Gespeichert in:
| Veröffentlicht in: | Cancers 2023-11, Vol.15 (23), p.5531 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 23 |
| container_start_page | 5531 |
| container_title | Cancers |
| container_volume | 15 |
| creator | Shin, Yong Jae Jo, Eun Hae Oh, Yunjeong Kim, Da Som Hyun, Seungyoon Yu, Ahran Hong, Hye Kyung Cho, Yong Beom |
| description | Colorectal cancer is the third most common cancer in the world, with an annual incidence of 2 million cases. The success of first-line chemotherapy plays a crucial role in determining the disease outcome. Therefore, there is an increasing demand for precision medicine to predict drug responses and optimize chemotherapy in order to increase patient survival and reduce the related side effects. Patient-derived organoids have become a popular in vitro screening model for drug-response prediction for precision medicine. However, there is no established correlation between oxaliplatin and drug-response prediction. Here, we suggest that organoid culture conditions can increase resistance to oxaliplatin during drug screening, and we developed a modified medium condition to address this issue. Notably, while previous studies have shown that survivin is a mechanism for drug resistance, our study observed consistent survivin expression irrespective of the culture conditions and oxaliplatin treatment. However, clusterin induced apoptosis inhibition and cell survival, demonstrating a significant correlation with drug resistance. This study's findings are expected to contribute to increasing the accuracy of drug-response prediction in patient-derived APC mutant colorectal cancer organoids, thereby providing reliable precision medicine and improving patient survival rates. |
| doi_str_mv | 10.3390/cancers15235531 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2902943257</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A775888771</galeid><sourcerecordid>A775888771</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-8e339c0518a92a2a436fe90608d0efb1dc0b76fef04e9fb780a7dbed4a656f83</originalsourceid><addsrcrecordid>eNptkUFPHSEUhUnTphp13V1D0k03owzMDLB8GbU10fjSuCcMXF4wM_AKM03678uobdUIC24u3zk5NxehTzU5ZUySM6ODgZTrlrK2ZfU7dEgJp1XXyeb9s_oAneR8T8phrOYd_4gOmCAdp6w7RPlq2qf4Cyw-T8uu-gF5H0MGvE1gvZl9DPgmWhhxdHiz7fHNMusw4z6O5ad_CIC3evYQ5uockl-dbtNOh-htxi6m1cn4_GC0WvoAx-iD02OGk6f3CN1dXtz136vr229X_ea6Mg1jcyWgTGlIWwstqaa6YZ0DSToiLAE31NaQgZeWIw1IN3BBNLcD2EZ3becEO0JfH23LgD8XyLOafDYwjjpAXLKiklDZMNrygn55hd7HJYUSTlEhZUOEFOQ_tdMjKB9cnJM2q6nacN4KITivC3X6BlWuhcmbGMD50n8hOHsUmBRzTuDUPvlJp9-qJmpdtHq16KL4_BR3GSaw__i_a2V_AOFyo5Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2899408980</pqid></control><display><type>article</type><title>Improved Drug-Response Prediction Model of APC Mutant Colon Cancer Patient-Derived Organoids for Precision Medicine</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Shin, Yong Jae ; Jo, Eun Hae ; Oh, Yunjeong ; Kim, Da Som ; Hyun, Seungyoon ; Yu, Ahran ; Hong, Hye Kyung ; Cho, Yong Beom</creator><creatorcontrib>Shin, Yong Jae ; Jo, Eun Hae ; Oh, Yunjeong ; Kim, Da Som ; Hyun, Seungyoon ; Yu, Ahran ; Hong, Hye Kyung ; Cho, Yong Beom</creatorcontrib><description>Colorectal cancer is the third most common cancer in the world, with an annual incidence of 2 million cases. The success of first-line chemotherapy plays a crucial role in determining the disease outcome. Therefore, there is an increasing demand for precision medicine to predict drug responses and optimize chemotherapy in order to increase patient survival and reduce the related side effects. Patient-derived organoids have become a popular in vitro screening model for drug-response prediction for precision medicine. However, there is no established correlation between oxaliplatin and drug-response prediction. Here, we suggest that organoid culture conditions can increase resistance to oxaliplatin during drug screening, and we developed a modified medium condition to address this issue. Notably, while previous studies have shown that survivin is a mechanism for drug resistance, our study observed consistent survivin expression irrespective of the culture conditions and oxaliplatin treatment. However, clusterin induced apoptosis inhibition and cell survival, demonstrating a significant correlation with drug resistance. This study's findings are expected to contribute to increasing the accuracy of drug-response prediction in patient-derived APC mutant colorectal cancer organoids, thereby providing reliable precision medicine and improving patient survival rates.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15235531</identifier><identifier>PMID: 38067236</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adenomatous polyposis coli ; Analysis ; Apoptosis ; Bevacizumab ; Cancer ; Cancer patients ; Cancer therapies ; Care and treatment ; Cell culture ; Cell survival ; Chemotherapy ; Clusterin ; Colon cancer ; Colorectal carcinoma ; Drug resistance ; Drug screening ; Health aspects ; Irinotecan ; Medical research ; Medicine, Experimental ; Mutants ; Organoids ; Oxaliplatin ; Patients ; Precision medicine ; Prediction models ; Scientific equipment and supplies industry ; Spheroids ; Survivin</subject><ispartof>Cancers, 2023-11, Vol.15 (23), p.5531</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-8e339c0518a92a2a436fe90608d0efb1dc0b76fef04e9fb780a7dbed4a656f83</citedby><cites>FETCH-LOGICAL-c433t-8e339c0518a92a2a436fe90608d0efb1dc0b76fef04e9fb780a7dbed4a656f83</cites><orcidid>0009-0008-2237-8051 ; 0000-0002-9944-4706</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38067236$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shin, Yong Jae</creatorcontrib><creatorcontrib>Jo, Eun Hae</creatorcontrib><creatorcontrib>Oh, Yunjeong</creatorcontrib><creatorcontrib>Kim, Da Som</creatorcontrib><creatorcontrib>Hyun, Seungyoon</creatorcontrib><creatorcontrib>Yu, Ahran</creatorcontrib><creatorcontrib>Hong, Hye Kyung</creatorcontrib><creatorcontrib>Cho, Yong Beom</creatorcontrib><title>Improved Drug-Response Prediction Model of APC Mutant Colon Cancer Patient-Derived Organoids for Precision Medicine</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Colorectal cancer is the third most common cancer in the world, with an annual incidence of 2 million cases. The success of first-line chemotherapy plays a crucial role in determining the disease outcome. Therefore, there is an increasing demand for precision medicine to predict drug responses and optimize chemotherapy in order to increase patient survival and reduce the related side effects. Patient-derived organoids have become a popular in vitro screening model for drug-response prediction for precision medicine. However, there is no established correlation between oxaliplatin and drug-response prediction. Here, we suggest that organoid culture conditions can increase resistance to oxaliplatin during drug screening, and we developed a modified medium condition to address this issue. Notably, while previous studies have shown that survivin is a mechanism for drug resistance, our study observed consistent survivin expression irrespective of the culture conditions and oxaliplatin treatment. However, clusterin induced apoptosis inhibition and cell survival, demonstrating a significant correlation with drug resistance. This study's findings are expected to contribute to increasing the accuracy of drug-response prediction in patient-derived APC mutant colorectal cancer organoids, thereby providing reliable precision medicine and improving patient survival rates.</description><subject>Adenomatous polyposis coli</subject><subject>Analysis</subject><subject>Apoptosis</subject><subject>Bevacizumab</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cell culture</subject><subject>Cell survival</subject><subject>Chemotherapy</subject><subject>Clusterin</subject><subject>Colon cancer</subject><subject>Colorectal carcinoma</subject><subject>Drug resistance</subject><subject>Drug screening</subject><subject>Health aspects</subject><subject>Irinotecan</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mutants</subject><subject>Organoids</subject><subject>Oxaliplatin</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Prediction models</subject><subject>Scientific equipment and supplies industry</subject><subject>Spheroids</subject><subject>Survivin</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkUFPHSEUhUnTphp13V1D0k03owzMDLB8GbU10fjSuCcMXF4wM_AKM03678uobdUIC24u3zk5NxehTzU5ZUySM6ODgZTrlrK2ZfU7dEgJp1XXyeb9s_oAneR8T8phrOYd_4gOmCAdp6w7RPlq2qf4Cyw-T8uu-gF5H0MGvE1gvZl9DPgmWhhxdHiz7fHNMusw4z6O5ad_CIC3evYQ5uockl-dbtNOh-htxi6m1cn4_GC0WvoAx-iD02OGk6f3CN1dXtz136vr229X_ea6Mg1jcyWgTGlIWwstqaa6YZ0DSToiLAE31NaQgZeWIw1IN3BBNLcD2EZ3becEO0JfH23LgD8XyLOafDYwjjpAXLKiklDZMNrygn55hd7HJYUSTlEhZUOEFOQ_tdMjKB9cnJM2q6nacN4KITivC3X6BlWuhcmbGMD50n8hOHsUmBRzTuDUPvlJp9-qJmpdtHq16KL4_BR3GSaw__i_a2V_AOFyo5Y</recordid><startdate>20231122</startdate><enddate>20231122</enddate><creator>Shin, Yong Jae</creator><creator>Jo, Eun Hae</creator><creator>Oh, Yunjeong</creator><creator>Kim, Da Som</creator><creator>Hyun, Seungyoon</creator><creator>Yu, Ahran</creator><creator>Hong, Hye Kyung</creator><creator>Cho, Yong Beom</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0008-2237-8051</orcidid><orcidid>https://orcid.org/0000-0002-9944-4706</orcidid></search><sort><creationdate>20231122</creationdate><title>Improved Drug-Response Prediction Model of APC Mutant Colon Cancer Patient-Derived Organoids for Precision Medicine</title><author>Shin, Yong Jae ; Jo, Eun Hae ; Oh, Yunjeong ; Kim, Da Som ; Hyun, Seungyoon ; Yu, Ahran ; Hong, Hye Kyung ; Cho, Yong Beom</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-8e339c0518a92a2a436fe90608d0efb1dc0b76fef04e9fb780a7dbed4a656f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenomatous polyposis coli</topic><topic>Analysis</topic><topic>Apoptosis</topic><topic>Bevacizumab</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cell culture</topic><topic>Cell survival</topic><topic>Chemotherapy</topic><topic>Clusterin</topic><topic>Colon cancer</topic><topic>Colorectal carcinoma</topic><topic>Drug resistance</topic><topic>Drug screening</topic><topic>Health aspects</topic><topic>Irinotecan</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mutants</topic><topic>Organoids</topic><topic>Oxaliplatin</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Prediction models</topic><topic>Scientific equipment and supplies industry</topic><topic>Spheroids</topic><topic>Survivin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shin, Yong Jae</creatorcontrib><creatorcontrib>Jo, Eun Hae</creatorcontrib><creatorcontrib>Oh, Yunjeong</creatorcontrib><creatorcontrib>Kim, Da Som</creatorcontrib><creatorcontrib>Hyun, Seungyoon</creatorcontrib><creatorcontrib>Yu, Ahran</creatorcontrib><creatorcontrib>Hong, Hye Kyung</creatorcontrib><creatorcontrib>Cho, Yong Beom</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shin, Yong Jae</au><au>Jo, Eun Hae</au><au>Oh, Yunjeong</au><au>Kim, Da Som</au><au>Hyun, Seungyoon</au><au>Yu, Ahran</au><au>Hong, Hye Kyung</au><au>Cho, Yong Beom</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improved Drug-Response Prediction Model of APC Mutant Colon Cancer Patient-Derived Organoids for Precision Medicine</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-11-22</date><risdate>2023</risdate><volume>15</volume><issue>23</issue><spage>5531</spage><pages>5531-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Colorectal cancer is the third most common cancer in the world, with an annual incidence of 2 million cases. The success of first-line chemotherapy plays a crucial role in determining the disease outcome. Therefore, there is an increasing demand for precision medicine to predict drug responses and optimize chemotherapy in order to increase patient survival and reduce the related side effects. Patient-derived organoids have become a popular in vitro screening model for drug-response prediction for precision medicine. However, there is no established correlation between oxaliplatin and drug-response prediction. Here, we suggest that organoid culture conditions can increase resistance to oxaliplatin during drug screening, and we developed a modified medium condition to address this issue. Notably, while previous studies have shown that survivin is a mechanism for drug resistance, our study observed consistent survivin expression irrespective of the culture conditions and oxaliplatin treatment. However, clusterin induced apoptosis inhibition and cell survival, demonstrating a significant correlation with drug resistance. This study's findings are expected to contribute to increasing the accuracy of drug-response prediction in patient-derived APC mutant colorectal cancer organoids, thereby providing reliable precision medicine and improving patient survival rates.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38067236</pmid><doi>10.3390/cancers15235531</doi><orcidid>https://orcid.org/0009-0008-2237-8051</orcidid><orcidid>https://orcid.org/0000-0002-9944-4706</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2023-11, Vol.15 (23), p.5531 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2902943257 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Adenomatous polyposis coli Analysis Apoptosis Bevacizumab Cancer Cancer patients Cancer therapies Care and treatment Cell culture Cell survival Chemotherapy Clusterin Colon cancer Colorectal carcinoma Drug resistance Drug screening Health aspects Irinotecan Medical research Medicine, Experimental Mutants Organoids Oxaliplatin Patients Precision medicine Prediction models Scientific equipment and supplies industry Spheroids Survivin |
| title | Improved Drug-Response Prediction Model of APC Mutant Colon Cancer Patient-Derived Organoids for Precision Medicine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T14%3A33%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improved%20Drug-Response%20Prediction%20Model%20of%20APC%20Mutant%20Colon%20Cancer%20Patient-Derived%20Organoids%20for%20Precision%20Medicine&rft.jtitle=Cancers&rft.au=Shin,%20Yong%20Jae&rft.date=2023-11-22&rft.volume=15&rft.issue=23&rft.spage=5531&rft.pages=5531-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15235531&rft_dat=%3Cgale_proqu%3EA775888771%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2899408980&rft_id=info:pmid/38067236&rft_galeid=A775888771&rfr_iscdi=true |